Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy, Trial To Commence In The Coming Months With The First Patients Enrolled In The U.S.
Benzinga_Newsdesk